Scientists have developed a new candidate for an AIDS vaccine

A Chinese-American research team has developed a vaccine candidate that is expected to enter human clinical trials in 2019 and hopefully give healthy people broad-spectrum immunity to HIV in the future, according to a study published Thursday in the British journal
.Anthony Folch, director of the National Institute of Allergy and Infectious Diseases, a
research institute, said that by accurately understanding the structure of the virus, researchers have found an unusually weak point in the virus and designed and developed an effective new vaccine candidate.
Xu Kai and Zhou Tongqing of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have previously found that fusion peptides on HIV are easily identified by antibodies produced by the immune system. During viral infection, fusion peptides on HIV lead to the fusion of the virus envelope and the body's cell membrane, allowing the virus to invade the cells.
In the new study, Xu Kai and Zhou Tongqing and others designed and developed a new candidate vaccine for the characteristics of this fusion peptide, so that the body's immune response focuses on the special weak points on this fusion peptide, effectively prompting the body to produce broad-spectrum and antibodies, so that the body is immune to the virus.Zhou Tongqing,
, told Xinhua that there are several types of fusion peptide sequence changes, researchers inoculated mice with one of the fusion peptide sequence types of vaccine found that the sequence matching representative HIV strains can be suppressed. Recent advances have shown that the vaccine has also had good antiviral effects in guinea pigs and monkeys. No previous vaccine study has produced such broad-spectrum antibodies in experimental animal models.
researchers say that usually only a small number of people living with HIV can produce broad-spectrum neutral antibodies years after infection, and the new vaccine candidates are expected to allow healthy people to produce protective antibodies shortly after vaccination. Future clinical applications could use monocerical vaccines or a combination of several types of multi-priced vaccines that fuse peptides to fight most endemic HIV strains. (Source: Xinhua News Agency, Zhou zhou)
related links: